Switching from injectable to other Disease Modifying Therapies may improve sexual dysfunction in people with Multiple Sclerosis

被引:1
作者
Ala, Sara [1 ]
Amirkafi, Ali [2 ]
Kohandel, Kosar [1 ]
Shahmohammadi, Sareh [1 ]
Sahraian, Mohammad Ali [1 ]
机构
[1] Univ Tehran Med Sci, Neurosci Inst, Multiple Sclerosis Res Ctr, Tehran, Iran
[2] Iran Univ Med Sci, Tehran, Iran
关键词
Multiple sclerosis; Sexual function; Sexual dysfunction; Disease modifying therapies; QUALITY-OF-LIFE; DIMETHYL FUMARATE; OPEN-LABEL; NATALIZUMAB; PREVALENCE; FINGOLIMOD; OUTCOMES; PATIENT; MS;
D O I
10.1186/s12883-024-03765-2
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BackgroundMultiple Sclerosis (MS) a central nervous system autoimmune disorder, mainly affecting young adults and more prevalent among women, can lead to sexual dysfunction (SD) among both males and females with MS. Female sexual dysfunction can be defined as dyspareunia, a lack of sexual desire, disorders in the arousal and orgasm phases, and sexual pain disorders. The purpose of this study is to investigate the changes in sexual function among females with MS whose treatment was switched from first-line injectable medications to other agents after a six-month duration. And assess the changes in all three domains of SD.MethodsIn this longitudinal study females diagnosed with MS, aged between 18 and 50 years old, and were candidates for switching their treatment from interferon beta-1a (intra-muscular and subcutaneous), and Glatiramer Acetate (GA), to Fingolimod, Dimethyl Fumarate (DMF), or Natalizumab (NTZ) due to patients' convenience and tolerability and adverse events were included. "Multiple Sclerosis Intimacy and Sexuality Questionnaire-19" was used to evaluate the SD changes before and six months after the new treatment initiation. Statistical analysis was conducted using SPSS V.24 software. Histograms and the Shapiro-Wilk test were used to assess the normality of the variables; due to the non-normal distribution of quantitative variables (except for age), the Wilcoxon signed-rank test was used to compare the scores, before and six months after the medication change. The level of significance was considered less than 0.05.ResultsOut of 107 female participants (average age: 35.09 +/- 5.61), The mean of overall MSISQ-19 scores, before and six months after the medication change were not significant (p-value = 0.091). However, considering the subdomains, the medication changes only affected the tertiary subdomain of MSISQ-19 (p-value = 0.017). Still, the scores of other subdomains did not change significantly (p-value = 0.761 for primary SD and 0.479 for secondary SD). Also, there wasn't any significant difference between EDSS before and after the medication change (p-value = 0.461).ConclusionsTo our knowledge, this was the first study, assessing the effect of MS medication change on the improvement of SD among patients. According to the results of the presented cross-sectional study, we found that during a six-month period, the tertiary subdomain of MSISQ-19 symptoms improved significantly, while the changes in other SD domains were not significant.
引用
收藏
页数:6
相关论文
共 44 条
  • [1] Abolfazli R, 2012, International Scholarly Research Notices, V2012
  • [2] Correlation of disability with quality of life in patients with multiple sclerosis treated with natalizumab: primary results and post hoc analysis of the TYSabri ImPROvement study (PROTYS)
    Achtnichts, Lutz
    Zecca, Chiara
    Findling, Oliver
    Kamm, Christian P.
    Mueller, Stefanie
    Kuhle, Jens
    Lutterotti, Andreas
    Gobbi, Claudio
    Viviani, Camille
    Villiger-Borter, Emanuela
    Nedeltchev, Krassen
    [J]. BMJ NEUROLOGY OPEN, 2023, 5 (01)
  • [3] The most effective sexual function and dysfunction interventions in individuals with multiple sclerosis: A systematic review and meta-analysis
    Afshar, Bahare
    Amini, Leila
    Hasani, Maryam
    Jahanfar, Shayesteh
    Nabavi, Seyed Massood
    [J]. INTERNATIONAL JOURNAL OF REPRODUCTIVE BIOMEDICINE, 2022, 20 (04) : 241 - 254
  • [4] Azimi Amirreza, 2019, Maedica (Bucur), V14, P408, DOI 10.26574/maedica.2019.14.4.408
  • [5] Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review
    Balak, Deepak M. W.
    Hengstman, Gerald J. D.
    Cakmak, Aysun
    Thio, H. Bing
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (12) : 1705 - 1717
  • [6] Sexual dysfunction in female patients with relapsing-remitting multiple sclerosis
    Bartnik, Pawel
    Wielgos, Aleksandra
    Kacperczyk, Joanna
    Pisarz, Katarzyna
    Szymusik, Iwona
    Podlecka-Pietowska, Aleksandra
    Zakrzewska-Pniewska, Beata
    Wielgos, Miroslaw
    [J]. BRAIN AND BEHAVIOR, 2017, 7 (06):
  • [7] Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial
    Calkwood, Jonathan
    Cree, Bruce
    Crayton, Heidi
    Kantor, Daniel
    Steingo, Brian
    Barbato, Luigi
    Hashmonay, Ron
    Agashivala, Neetu
    McCague, Kevin
    Tenenbaum, Nadia
    Edwards, Keith
    [J]. BMC NEUROLOGY, 2014, 14
  • [8] Physical Exercise Moderates the Effects of Disability on Depression in People with Multiple Sclerosis during the COVID-19 Outbreak
    Carotenuto, Antonio
    Scandurra, Cristiano
    Costabile, Teresa
    Lavorgna, Luigi
    Borriello, Giovanna
    Moiola, Lucia
    Inglese, Matilde
    Trojsi, Francesca
    Petruzzo, Martina
    Ianniello, Antonio
    Nozzolillo, Agostino
    Cellerino, Maria
    Boffa, Giacomo
    Rosa, Laura
    Chiodi, Alessandro
    Servillo, Giuseppe
    Moccia, Marcello
    Bonavita, Simona
    Filippi, Massimo
    Petracca, Maria
    Brescia Morra, Vincenzo
    Lanzillo, Roberta
    [J]. JOURNAL OF CLINICAL MEDICINE, 2021, 10 (06) : 1 - 7
  • [9] Sexual dysfunction in multiple sclerosis: Gender differences
    Celik, Dilaram Billur
    Poyraz, Esra Coskuner
    Bingol, Ayhan
    Idiman, Egemen
    Ozakbas, Serkan
    Kaya, Derya
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2013, 324 (1-2) : 17 - 20
  • [10] The relationship between dimensions of mental health and alexithymia in multiple sclerosis patients
    Christopoulos, Anna L.
    Poulios, Antonios
    Pavlopoulos, Vassilis
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 46